NASDAQ
10.86USD
+0.24 (+2.26%)
We have scored 21 news catalysts on QuidelOrtho Corporation (QDEL) over the past 12 months. The biggest single-day move next to one of them came Aug 7, 2026, when QDEL closed −24.7%: “Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket”. Coverage across the window leans positive (average ticker sentiment +0.14). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
740.6M
P/E
—
EPS
—
Beta
0.68
52W range
9.92-35.58
Day range
10.39–10.97
Open
10.75
Prev close
10.62
Volume
1.1M
Avg volume
1.6M
Dividend
0.00
IPO
1991-02-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about QuidelOrtho Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for QDEL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
